A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer. [Cancer Res 2007;67(3):851-3] 
Introduction
Complete and permanent success of cancer therapy depends on the targeting of all tumor cells (including cancer stem cells) or, alternatively, on the direct removal of a part of the tumor, escorted by a ''bystander effect'' in which the immune system recognizes, attacks, and eradicates remaining tumor cells. Our group found two examples of such a bystander effect promoted by immune cells. First, anthracycline-treated tumor cells could elicit a dendritic cell (DC)-mediated cytotoxic T cell (CTL) response that conferred stable longterm protection against rechallenge with the same tumor (1) . This effect depended on the apoptogenic agent, on the form of cell death, on the innate immune system, as well as on the cognate immune system. Second, inhibition of the c-kit tyrosine kinase by the paradigmatic anticancer drug, Gleevec/STI571, could endow DC with natural killer (NK) cell stimulatory capacity in mice and humans, leading to prolonged survival in patients bearing gastrointestinal sarcoma (2) . In attempting to dissect the immune mechanisms leading to drug-induced tumor rejection, we recently discovered a new player in innate immunity that we called ''IFN-producing killer dendritic cells'' (IKDC), for its ability to produce IFNg and to recognize tumor cells that are resistant to classic NK cells (3).
Key Findings Leading to the Discovery of IKDC
As recently reported, c-kit tyrosine kinase inhibitors such as Gleevec/STI571 can stimulate a host-dependent antitumor activity involving myeloid DC-primed NK cells (2) . With the aim of further improving the NK cell-mediated antitumor effect induced by Gleevec/STI571, we combined Gleevec/STI571 with interleukin 2 (IL-2) and observed enhanced antitumor effects against B16F10 melanoma lung metastases, as compared with either agent alone.
Administration of depleting anti-NKR-P1c/NK1.1 monoclonal antibody completely abrogated the tumoricidal activity induced by the combination of Gleevec/STI571 and IL-2, suggesting a role for NK1.1 expressing cells.
Immunohistochemistry of regressing lung metastases in Gleevec/ STI571+IL-2-treated mice revealed prominent infiltrates of CD11c + cells in tumor beds and in surrounding parenchyma, suggesting that DC might be critical effectors of the antitumor effects achieved with the combination therapy ( Fig. 1 Analyses using light microscopy and transmission electron microscopy highlighted that freshly isolated IKDC have a unique morphology. IKDC do not resemble pDC (with their developed and pathognomonic endoplasmic reticulum), display a smooth plasma membrane with small pseudopodia, a high nucleocytoplasmic ratio and a dense cytoplasm containing few mitochondria but numerous granules ( Fig. 1; refs. 3, 4) .
Role of IKDC in Tumor Immunotherapy
Death receptors were found to be involved in the tumoricidal activity promoted by the combination therapy using Gleevec/ STI571+IL-2. B16F10 tumor cells manipulated to express proteins that block the proapoptotic signal transduction complex initiated via death receptors (such as the dominant-negative mutant for Fas-associated death domain or the cowpox virus caspase-8 inhibitor CrmA) were resistant to this combination therapy in vivo. + cells. Flow cytometry analyses of lung metastases gating on CD11c + cells revealed that they coexpressed B220 and NK1.1, but not Gr1, and analyses in blood and spleen showed an increase of this cell population under treatment. Light microscopy (May Grü nwald Giemsa) and electron microscopy of IKDC highlighted their small size, the high nucleocytoplasmic ratio, and the abundance of granules in the cytoplasm.
Cancer Research
Cancer Res 2007; 67: (3 (5), we further examined the regulation of IFNg secretion by IKDC and NK cells. Strikingly, IKDC stimulated in vitro with tumor cells produced large amounts of IFNg. Stimulation of IKDC with Gleevec/STI571+IL-2 also resulted in the secretion of IFNg. Remarkably, IKDC could produce IFNg in response to a broad array of allogeneic or syngeneic transformed cells except the transporter for antigen processingdeficient RMA-S cells, whereas NK cells failed to do so in the absence of exogenous stimulation, albeit exhibiting lytic activity against RMA-S. It is of note that IKDC did not secrete IFNg in contact with healthy tissues such as primary hepatocyte or thymocyte cultures.
In conclusion, IKDC might mediate their tumoricidal activity by IFNg secretion and TRAIL-dependent direct tumor cell lysis.
Chief Implications
This review describes the discovery of a novel DC subset called IKDC, a multitasking chimera sharing the phenotypic and functional properties of both DC and NK cells (3, 4, 6) . Indeed, lytic IKDC express MHC class II and CD86 molecules and secrete large amounts of IFNg in contact with transformed cells (whereas NK cells fail to do so). IKDC display the cardinal feature of DC, i.e., the capacity of antigen presentation following activation with TLR9 ligands as published by Chan et al., who characterized and described IKDC in parallel to our group in BALB/c mouse (4) .
These data open up the following prospects:
First, we propose that IKDC constitute a privileged link between the innate and cognate arms of antitumor immunity.
The current paradigm for T cell priming following tissue destruction relies on a two-step process whereby the tumor cell death event is somewhat dissociated from the antigen presentation in lymph nodes. Hence, apoptotic tumor cells might release endogenous danger signals that could activate conventional DC (cDC). The CTL or NK attack of tumors could liberate tumor antigens available for cDC and promote the translocation or secretion of endogenous alarmins that could activate surrounding cDC (7) . Alternatively, a one-step process could be envisioned in which a single cell would be able to kill tumor targets, uptake apoptotic debris, and initiate its differentiation towards a bona fide antigen-presenting cell. Such a scenario is conceivable because Chan et al. showed that IKDC express L-selectin and CCR7 and can traffic from blood to T cell areas of lymphoid organs, where they exhibit a DC phenotype (losing NKG2D and acquiring CD40; ref. (9) . However, the precise nature of the cell capable of both, killing and antigen presentation, has not been established before we published our study.
Second, our data suggest that the combination therapy with Gleevec/STI571+IL-2 (which involves IKDC that trigger TRAILdependent apoptosis of tumor cells) could be implemented in the clinic, in particular, in TRAIL-sensitive cancers that are resistant to the direct antiproliferative effect of Gleevec/STI571. Consequently, identifying the human counterparts of mouse IKDC remains an important challenge.
Third, the implication of the host immune system in antitumor effects mediated by chemo-or radiotherapy is being actively investigated (10) . Certain cell death modalities might electively trigger innate and/or adaptive immune responses, thus eliciting an antitumor response mediated by the host (1, 11) . The challenge is now to transpose these data to the human system and to decipher the exact role of IKDC in the immune system's fight against cancer.
